Inhibitor Therapeutics, Inc. (INTI) stock
INTIOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 1/30
$0.11+0.00 (+0.09%)
Close on Oct 19, 2026Market cap $19.06MP/E –Yield –
Inhibitor Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Inhibitor Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$3.22M. For fiscal 2025 it was -$3.23M. The highest annual figure on record is $11.74M in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.23M | – |
| FY2024 | Dec 31, 2024 | -$3.23M | – |
| FY2023 | Dec 31, 2023 | -$2.70M | -123.0% |
| FY2022 | Dec 31, 2022 | $11.74M | – |
| FY2021 | Dec 31, 2021 | -$220.43K | – |
| FY2020 | Dec 31, 2020 | -$825.36K | – |
| FY2019 | Dec 31, 2019 | -$2.71M | – |
| FY2018 | Dec 31, 2018 | -$3.71M | – |
| FY2017 | Dec 31, 2017 | -$2.91M | – |
| FY2016 | Dec 31, 2016 | -$3.76M | – |
| FY2015 | Dec 31, 2015 | -$2.26M | – |
| FY2014 | Dec 31, 2014 | -$1.30M | – |
| FY2013 | Dec 31, 2013 | -$1.22M | – |
| FY2012 | Dec 31, 2012 | -$464.27K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$775.22K | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.08M | – |
| Q4 FY2025 | Dec 31, 2025 | -$601.17K | – |
| Q3 FY2025 | Sep 30, 2025 | -$761.25K | – |
| Q2 FY2025 | Jun 30, 2025 | -$583.99K | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.28M | – |
| Q4 FY2024 | Dec 31, 2024 | -$771.44K | – |
| Q3 FY2024 | Sep 30, 2024 | -$720.44K | – |
| Q2 FY2024 | Jun 30, 2024 | -$583.08K | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.16M | – |
| Q4 FY2023 | Dec 31, 2023 | -$697.71K | -105.9% |
| Q3 FY2023 | Sep 30, 2023 | -$562.71K | – |
| Q2 FY2023 | Jun 30, 2023 | -$682.61K | – |
| Q1 FY2023 | Mar 31, 2023 | -$757.28K | – |
| Q4 FY2022 | Dec 31, 2022 | $11.90M | – |
| Q3 FY2022 | Sep 30, 2022 | -$51.89K | – |
| Q2 FY2022 | Jun 30, 2022 | -$61.49K | – |
| Q1 FY2022 | Mar 31, 2022 | -$44.19K | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.66K | – |
| Q3 FY2021 | Sep 30, 2021 | -$40.43K | – |
| Q2 FY2021 | Jun 30, 2021 | -$65.47K | – |
| Q1 FY2021 | Mar 31, 2021 | -$91.87K | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.65K | – |
| Q3 FY2020 | Sep 30, 2020 | -$100.61K | – |
| Q2 FY2020 | Jun 30, 2020 | -$206.97K | – |
| Q1 FY2020 | Mar 31, 2020 | -$501.13K | – |
| Q4 FY2019 | Dec 31, 2019 | -$568.37K | – |
| Q3 FY2019 | Sep 30, 2019 | -$553.84K | – |
| Q2 FY2019 | Jun 30, 2019 | -$605.52K | – |
| Q1 FY2019 | Mar 31, 2019 | -$977.99K | – |
| Q4 FY2018 | Dec 31, 2018 | -$832.11K | – |
| Q3 FY2018 | Sep 30, 2018 | -$954.93K | – |
| Q2 FY2018 | Jun 30, 2018 | -$789.54K | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.13M | – |
| Q4 FY2017 | Dec 31, 2017 | -$543.25K | – |
| Q3 FY2017 | Sep 30, 2017 | -$756.05K | – |
| Q2 FY2017 | Jun 30, 2017 | -$745.91K | – |
| Q1 FY2017 | Mar 31, 2017 | -$867.88K | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.21M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.06M | – |
See a number that looks wrong?